More on the NRC Report

After reading the article by Paul Smaglik and Eugene Russo on the National Research Council's Commission on Life Sciences (The Scientist, 12[19]:6, Sept. 28, 1998), I was left with mixed emotions. On one hand, it was satisfying to see that the perception of a tight job market for Ph.D.-level scientists is being addressed seriously on a national level. I wrote about this problem over three years ago in The Scientist (9[11]:11, May 29, 1995), so naturally I believe that it would clearly be a good

Written byJames Fleet
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

After reading the article by Paul Smaglik and Eugene Russo on the National Research Council's Commission on Life Sciences (The Scientist, 12[19]:6, Sept. 28, 1998), I was left with mixed emotions. On one hand, it was satisfying to see that the perception of a tight job market for Ph.D.-level scientists is being addressed seriously on a national level. I wrote about this problem over three years ago in The Scientist (9[11]:11, May 29, 1995), so naturally I believe that it would clearly be a good thing if the production of Ph.D.s was limited in some way.

However, the suggestion (by Sherrie Hans) that students should only be permitted to be funded from National Institutes of Health training grants misses several critical points. First, the important feature of good training during graduate school is not just the size of a program (which is a clear determinant of whether a program or ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies